1	High-Dimensional Single-Cell Multimodal Landscape of Human Carotid Atherosclerosis
2	
3	Alexander C. Bashore <sup>1†</sup> , Hanying Yan <sup>2†</sup> , Chenyi Xue <sup>1</sup> , Lucie Y. Zhu <sup>1</sup> , Eunyoung Kim <sup>1</sup> , Thomas
4	Mawson <sup>1</sup> , Johana Coronel <sup>1</sup> , Allen Chung <sup>1</sup> , Sebastian Ho <sup>1</sup> , Leila S. Ross <sup>1</sup> , Michael Kissner <sup>3</sup> ,
5	Emmanuelle Passegué <sup>3</sup> , Robert C. Bauer <sup>1</sup> , Lars Maegdefessel <sup>4,5,6</sup> , Mingyao Li <sup>2+</sup> , Muredach P.
6	Reilly <sup>1,7†</sup>
7	
8	<sup>1</sup> Division of Cardiology, Department of Medicine, Vagelos College of Physicians and Surgeons,
9	Columbia University, New York.
10	
11	<sup>2</sup> Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania
12	Perelman School of Medicine, Philadelphia, PA
13	2
14	<sup>3</sup> Columbia Stem Cell Initiative, Department of Genetics and Development, Columbia University
15	Irving Medical Center, New York
16	
17	Department of Vascular and Endovascular Surgery, Technical University Munich, Germany
18	
19	German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance
20	<sup>6</sup> Karalinkas kastituta. Danartmant of Madiaina
21	karolinksa institute, Department of Medicine
22	<sup>7</sup> Inving Institute for Clinical and Translational Persoarch, Columbia University Inving Medical
20	Contor Now York NY
2 <del>4</del> 25	Center, New York, NT
26	These authors contributed equally
27	
28	*Correspondence: mpr2144@cumc.columbia.edu.or.mingvao@pennmedicine.upenn.edu
29	

## 30 Abstract

31

32 Background:

33

Atherosclerotic plaques are complex tissues composed of a heterogeneous mixture of cells.
 However, we have limited understanding of the comprehensive transcriptional and
 phenotypical landscape of the cells within these lesions.

- 37
- 38 Methods:
- 39

To characterize the landscape of human carotid atherosclerosis in greater detail, we combined cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) and single-cell RNA sequencing (scRNA-seq) to classify all cell types within lesions (n=21; 13 symptomatic) to achieve a comprehensive multimodal understanding of the cellular identities of atherosclerosis and their association with clinical pathophysiology.

- 45
- 46 Results:
- 47

48 We identified 25 distinct cell populations each having a unique multi-omic signature, including 49 macrophages, T cells, NK cells, mast cells, B cells, plasma cells, neutrophils, dendritic cells, 50 endothelial cells, fibroblasts, and smooth muscle cells (SMCs). Within the macrophage 51 populations, we identified 2 proinflammatory subsets that were enriched in IL1B or C1Q 52 expression, 2 distinct TREM2 positive foam cell subsets, one of which also expressed 53 inflammatory genes, as well as subpopulations displaying a proliferative gene expression 54 signature and one expressing SMC-specific genes and upregulation of fibrotic pathways. An in-55 depth characterization uncovered several subsets of SMCs and fibroblasts, including a SMC-56 derived foam cell. We localized this foamy SMC to the deep intima of coronary atherosclerotic 57 lesions. Using CITE-seq data, we also developed the first flow cytometry panel, using cell 58 surface proteins CD29, CD142, and CD90, to isolate SMC-derived cells from lesions. Last, we 59 found that the proportion of efferocytotic macrophages, classically activated endothelial cells, 60 contractile and modulated SMC-derived cell types were reduced, and inflammatory SMCs were 61 enriched in plaques of clinically symptomatic vs. asymptomatic patients.

- 62
- 63 Conclusions:
- 64

Our multimodal atlas of cell populations within atherosclerosis provides novel insights into the diversity, phenotype, location, isolation, and clinical relevance of the unique cellular composition of human carotid atherosclerosis. This facilitates both the mapping of cardiovascular disease susceptibility loci to specific cell types as well as the identification of novel molecular and cellular therapeutic targets for treatment of the disease.

#### 70 Introduction

71

72 Atherosclerosis, the major underlying cause of cardiovascular diseases (CVD), is a chronic 73 inflammatory disease that is initiated by the infiltration and modification of circulating low-74 density lipoproteins into the subendothelial space. As the disease initiates and progresses, 75 continuous recruitment of circulating immune cells contributes to a complex inflammatory 76 microenvironment. Additionally, smooth muscle cells (SMCs) migrate from the arterial media 77 into the developing lesion, where they undergo phenotypic modulation and transition to a 78 variety of cell fates including foam cells, macrophage-like cells, synthetic extracellular matrix-79 producing fibrotic cells, and osteogenic-like cells. Emerging genetic and experimental data 80 suggest that specific SMC-derived cell types are detrimental and contribute to plague instability 81 (e.g., macrophage and osteogenic types), whereas others are protective and contribute to plaque stability (e.g., fibrotic cell types)<sup>1</sup>. Increased proportions of pro-inflammatory cells 82 83 relative to matrix-producing cells within the lesion appear to increase plague vulnerability and 84 the likelihood of rupture, leading to clinical manifestations such as myocardial infarction and 85 ischemic stroke<sup>2</sup>.

86

87 Histological studies have identified culprit lesions as having a thin fibrous cap, large necrotic core, and an overabundance of immune cells like macrophages and T cells<sup>3,4</sup>. Moreover, recent 88 genome-wide association studies (GWAS) have identified many genetic loci associated with 89 90 CVD<sup>5</sup>, and many of these have been mapped to genes that modulate disease specifically 91 through SMC-derived cell, endothelial cell (EC), or immune cell functions. However, these 92 discoveries have translated into new therapies since the cellular mechanisms driving this 93 complex process have yet to be elucidated fully, cell and molecular mechanistic and causal 94 studies are lacking for most loci, and because mechanistic mouse models may not fully 95 recapitulate the complexity of human atherosclerosis<sup>6</sup>.

96

97 Recently, there has been an effort to characterize all cell types in human atherosclerosis by 98 utilizing rapidly evolving single-cell technologies to identify cell type-specific candidate genes 99 and molecular mechanisms and to drive novel therapies for atherosclerosis. These studies have 100 relied primarily on single-cell RNA sequencing (scRNA-seq), which uncovers cellular 101 heterogeneity by identifying subpopulations of cells with distinct transcriptional profiles in 102 atherosclerotic plaques. In one study, a multi-omic approach identified innate and adaptive immune cell alterations in carotid plaques associated with clinical events<sup>8</sup>. In another important 103 104 study, a vast heterogeneity of all cell types was revealed using combined scRNA-seq and single-105 cell ATAC sequencing to profile immune and nonimmune cells in human carotid atherosclerosis<sup>9</sup>. To date, these studies have been relatively small in scale and have not 106 107 provided a precise reference of cell types and canonical protein markers to facilitate clinical and 108 therapeutic translation. To achieve greater precision, we performed CITE-seq utilizing a large 109 panel of antibodies on carotid atherosclerotic plagues in combination with scRNA-seq. Here we 110 report the most comprehensive phenotypic and transcriptional landscape of all cell types within 111 advanced carotid atherosclerosis and identify cell-type specific protein markers as well as 112 perturbed activation states associated with cardiovascular events in the largest set of human 113 samples to date.

114

#### 115 Methods

116

#### 117 Human studies

118 All human subjects research in this study, including the use of human tissues, conformed to the 119 principles outlined in the Declaration of Helsinki. All patient information was de-identified. For 120 single-cell studies, tissues from human carotid atherosclerotic plagues were collected from 121 twenty-one patients undergoing carotid endarterectomy surgery. These human subject studies 122 were performed with approval (protocol number AAAJ2765) of the local Institutional Review 123 Board (IRB) of Columbia University Irving Medical Center, and written informed consent was 124 obtained from all participants. Exclusion criteria include current infection, known immune 125 system disorder, and active or recent (within last three months) radiation, chemotherapy, 126 hormone-based, and/or immunotherapy treatment for cancer. Table S1 summarizes the 127 demographic and clinical characteristics of the entire cohort, and subgroups to perform 128 comparative analysis. Symptomatic patients were defined as having a stroke or transient 129 ischemic attack (TIA) within 6 months of surgery. Asymptomatic patients had no history of 130 ischemic events. For arterial immunohistochemistry, human coronary artery tissues were 131 obtained from either donor hearts rejected for transplantation or explanted hearts during 132 cardiac transplant surgery. These human subject studies were performed with approval 133 (protocol number AAAR6796) of the local Institutional Review Board (IRB) of Columbia 134 University. Written informed consent was obtained upon admission before surgery.

135

#### 136 Atherosclerotic plaque cell dissociation for single-cell RNA-seq and CITE-seq preparation

137 Plaque specimens at endarterectomy were placed in phosphate buffered saline (PBS), 138 immediately transported to the laboratory, washed three times in PBS and minced into small 139 pieces. The tissue was then digested in RPMI 1640 containing Liberase (10 U/mL, Sigma cat no 140 5401127001), Elastase (8 U/mL, Sigma cat no E7885-20MG), and DNAse (120 U/mL, 141 Worthington cat no LS006331) at 37°C for 1 hour. The cell suspension was filtered through a 70-142 µm cell strainer, washed with double the volume of RPMI 1640 with 10% FBS, centrifuged at 143 400g for 5 min at 4°C, washed once with sterile-filtered FACS buffer (PBS + 2% FBS + 5mM EDTA 144 pH 8.0 + 20mM HEPES + 1mM sodium pyruvate), and spun down at 400g for 5 min at 4°C. For 145 CITE-seq, plaque specimens were dissociated the same way as for scRNA-seq and then 146 resuspended in 49uL of FACS buffer and 1uL of TruStain FcX (BioLegend cat no 422302) and 147 blocked for 10 minutes at room temperature. Following incubation, lyophilized oligo-148 conjugated antibodies (Table S2) were reconstituted in 50uL of FACS buffer and were added to 149 cell suspension and incubated for 30 minutes at 4°C. Then samples were washed 3 times in 150 FACS buffer with centrifugation at 400g for 5 min at 4°C. Single cell suspensions were stained 151 with Calcein AM (Thermo Fisher Scientific C34852) and Propidium Iodide (BioLegend 421301), 152 filtered through a 40-µM cell strainer and immediately brought to the flow cytometry core for 153 sorting. Viable cells were sorted on a BD FACSAria II and selected as being positive for Calcein 154 AM (488 nm excitation and 530/30 bandpass filter) and negative for Propidium Iodide (561 nm 155 excitation and a 610/20 bandpass filter). Doublets were excluded using forward light scatter 156 (FSC) signal area and height as customary. The FACSAria was set up using the 100 um nozzle at 157 20 PSI pressure, and cells were sorted using a one-drop purity (4-way Purity) mode. Cells were

158 collected in 1.5mL Eppendorf tubes containing DMEM/f12 + 10% FBS before pelleting and159 counting for 10x Genomics Chromium input.

160

## 161 **CITE-seq library preparation**

CITE-seq libraries were prepared as previously described<sup>7,10</sup> following 10x Genomics 3' v3 162 163 protocol according to manufacturer's instructions for cDNA amplification using 0.2 µM of ADT 164 additive primer (5'CCTTGGCACCCGAGAATTCC). The supernatant from the 0.6x SPRI cleanup 165 was saved and purified with two rounds of 2x SPRI, and final product was used as a template to 166 produce ADT libraries. Antibody tag libraries were generated by PCR using Kapa Hifi Master Mix 167 primer Biosciences KK2601), 10 mΜ 10x Genomics SI-PCR (Kapa 168 (5'AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTC), and Small RNA RPIx primer (5'CAAGCAGAAGACGGCATACGAGATxxxxxxGTGACTGGAGTTCCTTGGCACCCGAGAATTCCA 169 170 with xxxxxx denoting one of the four following sequences: CGTGAT, ACATCG, GCCTAA, 171 TGGTCA). Following amplification, Antibody tag libraries were cleaned up with 1.6x SPRI. 172 Subsequently, ADT quality was verified using a DNA high sensitivity assay on an Agilent 2100 173 bioanalyzer.

174

## 175 scRNA-seq and CITE-seq data pre-processing

scRNA-seq and CITE-seq FASTQ files were pre-processed by 10x Genomics Cell Ranger 5.0.1 to
generate count matrices with quality controls (QCs). Reference version 2020-A with GENCODE
v32 annotation was used. For CITE-seq libraries, an additional feature barcode reference was
included that contained IDs and sequences of 283 TotalSeq-A antibody-derived tags. Suffix was
added to gene symbols when multiple genes with different gene IDs shared the same gene
symbol.

182

## 183 Quality control (QC), normalization, and highly variable gene (HVG) selection

Using the Scanpy package in Python<sup>11</sup>, we first removed any cells expressing less than 200 184 185 genes, and then any genes expressed in less than 3 of the remaining cells with functions 186 "pp.filter cells" and "pp.filter genes". We also annotated the group of mitochondrial genes 187 and computed metrics with function "pp.calculate qc metrics". Cells with total UMI counts 188 over 40,000, or total mitochondrial genes proportion over 30%, or total unique genes over 189 6,000 were filtered out. Cells that pass QC filtering have gene expression normalized using a 190 two-step procedure: (1) Cell level normalization, in which the UMI count for a given gene in 191 each cell is divided by the total UMI count across all genes in the cell, multiplied by the median 192 total UMI count across all cells, and transformed to a natural log scale. (2) Gene level 193 normalization, in which the cell level normalized values for each gene are standardized by 194 subtracting the mean and dividing by the standard deviation across all cells within the same 195 batch for the given gene. HVGs were selected based on the log-normalized UMI counts using Butler<sup>12</sup> 196 and and the approach introduced by Stuart implemented in the 197 "pp.highly variable genes" function with "batch key" parameter in the Scanpy package. The 198 selected HVGs were used for downstream clustering analysis.

199

#### 200 Clustering and differential gene and protein expression analysis

CarDEC<sup>13</sup>, a published deep learning tool for scRNA-seq data batch effect correction, gene expression denoising, and clustering of cells, was applied on 15 scRNA-seq samples to get denoised gene expression on the z-score scale. CarDEC\_CITE, a modified version of CarDEC for CITE-seq data which preprocesses the gene and protein expression data separately, was utilized on 6 CITE-seq samples, generating denoised feature expression on the z-score scale and identifying 25 clusters.

207

208 Marker genes and proteins were detected using "tl.rank\_genes\_groups" in the Scanpy package 209 for each cluster identified, and the cell types were assigned based on the top features. Major

cell lineages were annotated using knowledge of known protein and gene markers for each cell

- 211 type from previously published flow cytometry and scRNA-seq studies<sup>14,15</sup>.
- 212

# 213 Integrative analysis of scRNA-seq and CITE-seq data

sciPENN is our published deep learning tool for integrative analysis of scRNA-seq and CITE-seq.
Leveraging information learned from CITE-seq data, sciPENN can predict protein expression in
scRNA-seq and transfer clustering labels from CITE-seq into scRNA-seq data<sup>16</sup>. Using sciPENN,
we integrated scRNA-seq and CITE-seq data into a shared latent low-dimensional space, which
was further dimension reduced and visualized using functions "sc.tl.pca", "sc.pp.neighbors" and
"sc.tl.umap" within Scanpy package.

219 220

# 221 Sub-clustering of macrophages, SMCs, and Fibroblasts

Among the 25 clusters obtained from the CITE-seq data, cells labeled as Myeloid (clusters 0, 3, 9, 11, 13, 19, 22), SMCs and Fibroblasts (clusters 2, 5, 12, 17, 18) were extracted, respectively. CarDEC was then performed to further cluster and identify the subpopulations. "tl.rank\_genes\_groups" was used to get marker genes and cell types were assigned based on them.

227

# 228 Differential gene expression and proportional analysis between symptomatic and 229 asymptomatic plaques

230 Among 21 samples, 13 are from symptomatic patients, and 8 are from asymptomatic patients. 231 For each cluster, pseudo-bulk RNA-seq analysis on the single-cell data was performed among the symptomatic and asymptomatic groups using DESeq2<sup>17</sup> package in R. Raw counts were 232 233 summed per gene per sample for cells in each cluster, pre-filtering was performed to keep 234 genes with at least 10 reads total, standard differential expression analysis was performed 235 using function "DESeq" and results were generated with function "results". For each cluster, we 236 also calculated the total cell counts proportion per sample, and unpaired two sample t test was 237 performed using "ttest ind" within scipy.stats package in Python to compare symptomatic and 238 asymptomatic groups.

239

# 240 Pathway analysis

241 Cell-type specific differentially expressed (DE) genes, with a Benjamini-Hochberg adjusted p-

- 242 value of less than 0.01 and  $\log_2$  fold change greater than 1, were uploaded into Ingenuity 242 Dethursu Applysis (IDA) software (OLACEN). IDA spectral that log a values and 3
- 243 Pathway Analysis (IPA) software (QIAGEN). IPA analysis reported the -log<sub>10</sub> p values and Z-

scores of canonical pathways and upstream regulators. The highest predicted upregulated
 canonical pathways and upstream regulators with a -log<sub>10</sub> p value > 1.3 for each cell population
 were selected for the respective analysis and visualized with either a heat map or radar plot.
 Full list of pathways can be found in **Table S4**.

249 Gene scoring analysis

250 To better characterize genes and pathways that are activated or repressed in cell populations, 251 we performed gene scoring analysis in human carotid plague scRNA-seq data. We first compiled 252 lists of genes involved in multiple cellular functions and pathways, including apoptosis, DNA 253 damage, macrophage efferocytosis, senescence, UPR response, and inflammasome. Cell cycle 254 genes, including 43 S phase genes and 54 G2/M phase genes from Tirosh et al.<sup>18</sup>, were extracted from Seurat package<sup>10</sup>, where gene symbols were updated. UMI counts were 255 256 normalized to a target total count of 10,000 per cell and then log-transformed. Gene scoring was performed using "scanpy.tl.score genes" function from Scanpy 1.9.1<sup>11</sup> with parameters 257 258 n bins = 24 and ctrl size = 100. Cell cycle scoring was performed using 259 "scanpy.tl.score genes cell cycle" function supplied with S phase genes and G2/M phase 260 genes above.

261

248

Gene scores were compared between cells from asymptomatic subjects and symptomatic subjects in each of the SMC, modulated SMC, fibroblast, macrophages, and endothelial cell populations. Wilcoxon rank-sum test was performed on each score between asymptomatic and symptomatic subjects in each cluster. P-values were adjusted by Benjamini-Hochberg method. Scores with adjusted P-value <0.05 were considered significantly different between asymptomatic and symptomatic subjects.

268

To compare gene score between multiple populations, we performed Kruskal-Wallis test across macrophage populations, SMCs and fibroblasts subpopulations. P-values were adjusted by Benjamini-Hochberg method in each set of analyses. For gene scores with adjusted P-value <0.05, Dunn's test was performed to identify pairs of populations that had significant differences in gene score distribution. P-values from Dunn's test were also adjusted by the Benjamini-Hochberg method.

275

# 276 M1 and M2 macrophage signature analysis

To characterize M1- and M2-macrophage functions in macrophage subpopulations, we utilized lists of M1 and M2 signature genes from Martinez et al.<sup>19</sup>. Genes from membrane receptors, cytokines and chemokines, apoptosis-related genes, solute carriers, enzymes, extracellular mediators, and DNA-binding factors were ordered by M1:M2 expression ratio. 54 genes with higher M1-macrophage expression and 43 genes with higher M2-macrophage expression were used to score macrophage subpopulations. Gene score comparison between populations was performed as described above.

- 284
- 285 Flow cytometry

286 Flow cytometry was performed on a frozen cell suspension from a plaque that was previously 287 submitted for scRNA-seq. Following thawing, cells were washed with FACS buffer and 288 centrifuged at 400g for 5 mins. The plaque cells were then blocked with TruStain FcX 289 (BioLegend cat no 101319) for 10 mins at room temperature. Subsequently, BD Brilliant Stain 290 Buffer (BD Biosciences 563794) and the following fluorescently conjugated antibodies were 291 added to the cells for 20 minutes at 4°C: CD45-APC/Cy7 (BioLegend 368515), CD142-APC 292 (BioLegend 365205), CD31-BV421 (BioLegend 303123), CD90-BUV496 (BD Biosciences 741160), 293 and CD29-PerCP-eFluor 710 (Thermo Fisher Scientific 46-0299-41). Cells were then washed 3 294 times with FACS buffer and viability dyes Calcein AM and Propidium Iodide were added. The 295 fluorescently labeled plaque cells were measured on a Novocyte Penteon and analyzed with 296 FlowJo software.

297

## 298 Immunohistochemistry of human coronary arteries

The left anterior descending coronary artery was excised from the myocardium and immediately placed into ice-cold RPMI, washed with RPMI to remove any blood, and cut into roughly 5mm sections and embedded in OCT. Blocks were immediately snap-frozen and stored at -80°C. For sectioning, tissue blocks were allowed to equilibrate at -20°C, sectioned into 8um thick sections, and mounted onto Superfrost Plus Microscope Slides.

304

305 For immunofluorescence, the sections were fixed with 4% paraformaldehyde for 20 minutes at 306 room temperature. After fixing, the sections were blocked in PBS containing 1% BSA and 10% 307 goat serum for 1 hour. The sections were then subsequently incubated with the following 308 primary antibodies, CD90 (1:200, Abcam ab181469) and Smoothelin (1:1000, Abcam 309 ab219652), overnight at 4°C in a humidified chamber. The next day, the sections were washed 310 with PBS and incubated with the appropriate secondary antibodies and LipidTOX Red (1:200, 311 Thermo Scientific H34476) for 1 hour at room temperature. Finally, the sections were 312 counterstained with DAPI and mounted with Invitrogen Prolong Glass Antifade Mountant 313 (Invitrogen P36982). Images were acquired with a Nikon A1 confocal microscope.

#### 314 Results

315

## 316 High-dimensional multi-omic profiling identifies 25 distinct cell populations in human 317 atherosclerotic plaques

318

319 To examine the single-cell transcriptome and cellular immunophenotypes of human atherosclerotic plaques, we performed multi-omic profiling on carotid endarterectomy tissue 320 321 from 21 patients. Tissue samples were digested enzymatically, and cells from six of these 322 patients were labeled with a panel of 274 CITE-seq antibodies before sequencing. Data were 323 integrated from 88,093 cells across all patients (CITE-seq and scRNA-seq) using our deep 324 learning model sciPENN, which also predicted protein expression in the query scRNA-seq dataset from the CITE-seq reference dataset<sup>16</sup> (Fig 1A). All cells were visualized by uniform 325 326 manifold approximation and projection (UMAP), revealing 25 distinct cell populations (Fig 1B). 327 Utilizing well-established canonical proteins, we identified 2 EC populations and 18 leukocyte 328 populations (Fig 1C and Suppl Fig 1), including all major immune cell types such as 329 macrophages, T cells, NK cells, B cells, plasma cells, mast cells, dendritic cells, and neutrophils. 330 Within macrophages, we observed 5 subtypes (Macrophage 1-5) that had high, near-ubiquitous 331 expression of major lineage markers such as CD64, CD11c, CD14, and MHCII. Three populations 332 of CD4<sup>+</sup> T cells (CD4<sup>+</sup> T Cell 1-3) and 2 populations of CD8<sup>+</sup> T cells (CD8<sup>+</sup> T Cell 1 and 2), 333 determined by CD3, CD7, CD2, and CD194 expression, were identified. Cluster 15, known to be 334 phenotypically like T cells, was distinguished by the specific expression of the NK cell markers 335 CD56 and CD16. B Cell 1, B Cell 2, and plasma cells were identified by the expression of CD19 336 and CD20, and KIT<sup>+</sup> mast cells were identified by expression of CD117. Two small dendritic cell 337 populations (clusters 19 and 22) that comprised plasmacytoid (pDC) and conventional DCs (cDC) 338 characterized by the expression of CD303 and CD141, respectively, were also identified. We 339 classified cluster 24 as neutrophils, which can be difficult to observe in scRNA-seq data, by the 340 expression of CD15. Similarly, we identified two EC clusters as having specific expression of the 341 proteins CD31, CD34, CD144, and CD49b.

342

343 Because SMCs and fibroblasts have not been immunophenotyped extensively, we used 344 canonical gene markers to identify these cell types (Fig 1D and Suppl Fig 2). To differentiate 345 SMCs and fibroblasts that clustered together by phenotypic similarities, we examined the 346 expression of known SMC genes ACTA2, MYH11, and CNN1, as well as fibroblast-specific genes 347 COL1A2, LUM, and LOXL1. This process revealed that clusters 5 and 12 (SMC 1 and 2) were 348 contractile SMCs with the highest expression of all SMC-related genes, whereas clusters 17 349 (SMC 3) and 18 (Modulated SMC) had lower expression of SMC genes. Modulated SMC had 350 higher expression of fibroblast genes relative to SMC 1 and 2, indicating that this SMC-derived 351 population has undergone phenotypic modulation. Cluster 2, with high expression of COL1A2, 352 LUM, and LOXL1, encompassed all fibroblasts in our dataset.

353

Next, we calculated the proportion of each cluster for each of the 21 individual subjects (**Suppl Figure 3A and B**). On aggregate, macrophages comprised 32% of the cells in our dataset, T cells S56 25%, SMCs 14%, fibroblasts 13%, and ECs 8% (**Fig 1E**). In contrast, other scRNA-seq studies have identified T cells as the dominant cell type in human carotid plaques<sup>8,9</sup>, perhaps due to

differences in digestion and isolation protocols or patient heterogeneity. Leukocytes comprised
 the largest proportions of cells within our carotid atherosclerosis dataset, consisting mainly of
 macrophages and T cells.

- 361
- 362 363

# Multimodal analysis provides deep understanding of plaque cellular phenotypes

- 364 To extend our findings beyond known cell surface protein markers, we used our CITE-seg data 365 to identify the distinct gene and protein signatures for all 25 populations depicted in Fig. 1B. To 366 assess the added value of incorporating both RNA and protein information into our analysis, we 367 calculated the gene and protein correlation for every gene-protein pair in our dataset for each 368 individual cluster. As shown in Fig 2A, overall, there was a high degree of correspondence 369 between protein and gene expression (Table S3), although it is well-established that there can be variability between protein levels and their coding transcripts<sup>20</sup>. In several circumstances, 370 the protein expression contributed critically to the identification of cell types when the RNA 371 372 was not highly expressed (Suppl Fig 4). For example, established neutrophil protein markers 373 CD15 and CD16 were highly expressed and specific although their corresponding genes, FUT4 374 and FCGR3A, were not detectable.
- 375

376 Our five macrophage clusters segregated into three major phenotypic classes. Macrophages 1 377 and 5 had high expression of FOLR2, cadherin 11 and CD93, suggesting roles in inflammation, 378 phagocytosis, and cell adhesion. In contrast, Macrophages 3 and 4 had high expression of CD36 379 and TREM1, suggesting a role in lipid uptake and metabolism. However, Macrophage 3 uniquely 380 expressed CD35, a receptor for complement activation. Macrophages 2 and 3 shared 381 expression of CLEC12A and CD192 (CCR2), indicating that they are more inflammatory and likely 382 recently recruited from circulation (Suppl Fig 5A). Macrophage 4 had the highest expression of 383 genes involved in lipid metabolism such as ABCA1, LPL, FABP5, and APOE, whereas 384 macrophages 2 and 3 had the highest expression of inflammatory genes such as IL1B, NLRP3, 385 and CCR2 (Suppl Fig 5B). Macrophages 1 and 5, notably, had intermediate expression of a 386 substantial proportion of genes involved in both functions. Because there was considerable 387 overlap in the gene expression profile of all macrophage subtypes, we identified which 388 upregulated and downregulated genes were unique to each population (Suppl Fig 5C). Using 389 this gene set, we performed pathway analysis to identify in more detail the predicted functional 390 differences between these populations (Suppl Fig 5D). This suggested both substantial 391 functional heterogeneity as well as degrees of overlap of plaque macrophages.

392

393 CITE-seq profiling was particularly helpful for characterizing SMC, fibroblasts, and ECs using 394 novel protein phenotypic markers. The SMC populations (SMC 1-3) had relatively uniform 395 expression of the proteins CD29, CD142, and EGFR. The modulated SMC population also had 396 relatively uniform expression of CD29 and EGFR but lacked expression of CD142. In contrast, 397 fibroblasts expressed CD90 to a similar degree as the modulated SMC populations, but 398 specifically expressed PDPN and CD13 (Fig 2B). Using the combination of these markers, we 399 developed a novel flow cytometry gating strategy to discriminate between SMC 1-3, modulated 400 SMCs, and fibroblasts (Fig 2C).

401

402 Our clustering also revealed two distinct EC populations (Fig 1B and C). To differentiate these, 403 we identified proteins that were expressed uniquely on one but not the other, e.g., CD49f, 404 CD112, and CD200 were expressed on endothelial cell 1 while CD62P, CD61, and CD201 were 405 highly expressed on endothelial cell 2 (Fig 2D). To delineate these cell types further, we 406 performed a differential expression analysis followed by pathway analysis using inferred 407 functional differences (Fig 2E). This analysis revealed that the endothelial cell 1 population 408 represented activated and inflamed endothelium, suggesting that this cluster promotes 409 leukocyte extravasation. In contrast, the endothelial cell 2 population had upregulation of 410 fibrotic pathways, suggesting that this cluster may be predisposed to undergo endothelial to 411 mesenchymal transition.

412

# 413 Cerebrovascular events are associated with dysregulation of macrophages as well as specific 414 smooth muscle cell, and endothelial cell subpopulations

415

416 UMAP visualization of samples revealed that the majority of clusters overlapped between 417 asymptomatic and symptomatic patient groups (Fig 3A, 3B). However, some striking differences 418 were identified, including reductions in the proportions of Macrophage 1, Endothelial Cell 1, 419 SMC 2, and modulated SMC populations, and a modest increase in SMC 3 population in 420 symptomatic patients (Fig 3C). The reduction in Macrophage 1, a macrophage population with 421 efferocytotic functions (Suppl Fig 6A), suggests that the capacity to clear dead and dying cells is 422 compromised. The decrease in the activated Endothelial Cell 1 population may suggest 423 increased plague erosion. The decrease in modulated SMCs and SMC 3 subpopulation increase suggests a shift to pro-inflammatory SMCs (Suppl Fig 6B). Unlike other studies<sup>8</sup>, we did not see 424 alterations in the proportion of T cell subpopulations (Suppl Fig 6C). Contrary to findings in 425 previous publications<sup>8</sup>, differential expression analysis revealed only three significant DE genes 426 427 associated with clinical status: S100A8, DDT, and PTGS1 (Suppl Fig 6D).

428

429 To assess biological processes that are associated with clinical events in more depth, we 430 performed a gene scoring analysis for macrophages, SMC, and fibroblasts. Generally, 431 macrophages in symptomatic plaques were more senescent (Fig 3D), exhibited a higher level of 432 ER stress through PERK activation, had a higher degree of inflammasome activation, but also 433 were pro-resolving (Suppl Fig 6E). Like macrophages, SMCs and fibroblasts from symptomatic 434 plaques were more senescent and PERK was more activated than were those from 435 asymptomatic plaques (Suppl Fig 6F). Also, SMCs and fibroblasts were more glycolytic 436 suggesting a metabolic shift in plaques associated with clinical events, as has been noted in plaques with features of plaque instability in mice<sup>21</sup> (Fig 3E). 437

438

# 439 Deep sub-clustering reveals diverse macrophages phenotypes in carotid plaques

440

441 Initial clustering identified 5 plaque macrophage clusters (Macrophage 1-5) (Figs. 1 and 2). To

explore cellular diversity more deeply, we performed a sub-clustering analysis on macrophage

443 and DC populations. This revealed 10 cell clusters, 7 macrophage subpopulations, 2 DC clusters,

444 and residual T cells expressing CD3 (Fig 4A and Suppl Fig 7A and B). From the initial clustering

445 (Suppl Fig 7C), Macrophage 1 mapped to clusters 0 and 4, Macrophage 2 mapped to cluster 1,

446 Macrophage 3 mapped to cluster 3, and Macrophage 4 mapped to clusters 2 and 5. In contrast, 447 Macrophage 5 was distributed throughout the subclusters. Cluster 7 was comprised of cells for 448 every macrophage population in the initial analysis. Clusters 0 and 1 were highly inflammatory, 449 expressing genes C1Q and IL1B, respectively, and enriched in inflammatory pathways (Fig 4B). 450 Clusters 2 and 4 expressed foam cell marker genes, in which cluster 2 expressed ABCA1, LPL, 451 CD36 and TREM2 most prominently, whereas cluster 4 expressed APOE in addition to 452 inflammatory genes like CCL18 and C1Q genes. Additionally, apoptotic (cluster 3), proliferative 453 (cluster 5), and  $ACTA2^+$  (cluster 7) subpopulations were identified. Cluster 3 showed 454 upregulation of the granzyme A apoptotic pathway (Fig 4B), along with high expression of 455 mitochondrial genes (Suppl Fig 7A and B). The proliferative subpopulation had specific 456 expression of many proliferation markers including MKI67, TUBB, and STMN1 (Suppl Fig 7B). 457 Finally, the  $ACTA2^{+}$  subpopulation (~6% of all macrophages) was, notably, characterized by high 458 expression of several SMC-related genes such as MYOCD, ACTA2, MYH11, and CNN1 (Suppl Fig 459 7B), along with protein expression of CD64, CD11c, and MHCII proteins (Suppl Fig 7D), 460 suggesting that it could represent phenotypic switching of SMCs to macrophage-like cells. This 461 subpopulation also exhibited upregulation of fibrotic signaling and epithelial-mesenchymal 462 transition pathways (Fig 4B).

463

464 To establish regulatory features of each macrophage subpopulation, we conducted an 465 upstream analysis using top DE genes and identified potential transcriptional regulators (Fig 466 **4C**). The C1Q<sup>hi</sup> (cluster 0) and IL1B<sup>hi</sup> (cluster 1) subpopulations shared regulatory features, like STAT1 and RELA, involved in immune modulation<sup>22,23</sup>. The proliferative subpopulation (cluster 467 468 5) exhibited the most specific regulatory features with high inferred regulation by the oncogene 469 *MYC.* The ACTA2<sup>+</sup> subpopulation showed inferred transcriptional regulation by MRTFB, MRTFA, NOTCH3, and SMAD3, known to control SMC differentiation<sup>24-27</sup>. To infer M1/M2 canonical 470 471 functional properties, we tested enrichment of M1- and M2-associated genes<sup>19</sup> in our dataset (Fig 4D). Only *IL1B<sup>hi</sup>* macrophages showed enrichment in M1 genes. Conversely, the *C1Q<sup>hi</sup>*, 472 473 foamy 1, foamy 2, and apoptotic subpopulations exhibited strong expression of M2 genes. The 474 proliferative and ACTA2<sup>+</sup> subpopulations did not show a strong M1 or M2 signature. These data align with literature suggesting that the M1/M2 classification inadequately captures the in vivo 475 476 phenotypic diversity of macrophages in atherosclerotic lesions<sup>28</sup>. 477

478 Although we did not observe any differences in macrophage subpopulations between 479 asymptomatic and symptomatic plaques (Suppl Fig 7E), we evaluated which cell populations 480 had upregulated gene expression for processes known to impact atherosclerosis. To do so, we utilized a list of genes involved in inflammasome activation, DNA damage and efferocytosis to 481 perform gene score analyses for these processes (**Fig 4E**). As expected, the *IL1B*<sup>hi</sup> subpopulation 482 483 was the only one with marked inflammasome activation. The proliferative subpopulation had highest expression of genes involved in DNA damage, while each of the C1Q<sup>hi</sup>, foamy 1, and 484 485 foamy 2 subpopulations had evidence for enhanced efferocytotic function.

486

## 487 Deep sub-clustering reveals multiple SMC and fibroblast subclasses in plaques

488

489 In initial clustering we identified 3 SMCs, 1 modulated SMC, and 1 fibroblast population (Figs. 1 490 and 2). This high-level clustering may not reveal the true heterogeneity within these cell types. 491 A recent study that performed snRNA-seq of human aortic tissue identified 7 SMC and 4 fibroblast populations<sup>29</sup>. Therefore, we performed a deep sub-clustering analysis on SMCs and 492 493 fibroblasts that revealed 10 unique clusters with specific gene expression profiles (Fig 5A). 494 Using classical SMC and fibroblast phenotypic markers (Fig 5B), we found that clusters 0 and 2 495 (major SMC 1 and 2) represented the two major classes of contractile SMCs with the highest 496 expression of MYH11 and ACTA2. Two smaller contractile SMC populations, clusters 4 and 6 497 (minor SMC 1 and 2), were also identified. Minor SMC 1 had moderate expression of MYH11 498 and TAGLN, but very low expression of other contractile SMC genes. Minor SMC 2 had 499 moderate expression of MYOCD, MYH11, and SMTN, but low levels of other SMC genes. The 500 most striking population was cluster 5, which had low expression of SMC genes and the specific 501 expression of many genes involved in lipid metabolism, suggesting that this large population 502 may be SMC-derived foam cells (Suppl Fig 9A). This foamy SMC cluster mapped almost 503 exclusively back to the modulated SMC population in the original analysis (Suppl Fig 9B). We 504 identified 3 fibroblast populations, clusters 1, 3, and 8, determined by the expression of BGN, 505 DCN, and COL1A1. Cluster 9, the last cluster identified, represented a fibromyocyte, having the 506 highest expression of VCAM1 and LY6E (Suppl Fig 9C).

508 To identify functional differences in the SMC subpopulations, we performed pathway analyses 509 of SMC and fibroblast sub-clusters. Consistent with annotation as prototypical contractile SMC 510 populations by DE gene analysis, our pathway analyses (Fig 5C) revealed that major SMC 1 and 511 2 were enriched for muscle functions, TGF- $\beta$  signaling, and actin cytoskeleton signaling. 512 Coincident with downregulation of contractile SMC genes, minor SMC 1 had upregulated 513 pathways involved in mRNA degradation and cell cycle regulation, suggesting that it might be 514 an actively dividing and proliferating subpopulation. Fibroblast clusters had upregulation of 515 several fibrotic pathways, and we found upregulation of necroptotic and apoptotic pathways in 516 the fibromyocytes (Fig 5D).

517

507

518 Since our data and those from recent mouse and human studies suggest that many foam cells may be SMC-derived<sup>30,31</sup>, we used a combination of markers revealed by CITE-seq and 519 520 functional inference to design an immunostaining protocol to spatially locate foamy SMCs in 521 human coronary artery sections. As noted, the foamy SMC cluster mapped primarily onto the 522 modulated SMC cluster in our initial analysis (Suppl Fig 9B), expressed the SMC-specific gene 523 smoothelin (Fig 5B), and highly expressed the protein CD90 (Suppl Fig 9D). At 524 immunohistochemistry of human coronary artery sections with a combination of smoothelin, 525 CD90, and LipidTOX (to identify foam cells) (Fig 5E), we revealed a sub-cluster of neointimal 526 cells that stained for all three markers, validating, and localizing modulated SMC-derived foamy 527 cells in human atherosclerotic lesions.

528

529 Given differences in SMC 2, SMC 3, and modulated SMCs by clinical status in our initial 530 clustering (**Fig 3C**), we examined the cell distributions by clinical events in our deep cell type 531 clustering and found subtle decreases in the proportions of foamy SMCs and fibromyocytes,

532 with a significant increase in minor SMC 2 and increased PERK activation in symptomatic 533 plaques (**Fig 5F and Suppl Fig 9E**).

#### 534 Discussion

#### 535

536 Through the largest and most in-depth scRNA-seq and high-dimensional CITE-seq phenotypic 537 characterization of human carotid atherosclerosis to date, we provide novel insights into the 538 cellular and molecular pathogenesis of atherosclerotic CVD. Our study reveals a comprehensive 539 landscape of 25 cell types, including macrophages and their regulatory features, 540 immunophenotypic and functional characterization of SMCs and fibroblasts, and cell type-541 specific perturbations associated with cerebrovascular events. We identified 7 macrophage, 3 542 fibroblast, and 7 SMC subpopulations, including 3 phenotypically modulated or 'switched' SMC 543 subpopulations. Each cell population displayed a distinct gene and protein expression signature, 544 reflecting their unique functions. For the first time, we also offer marker panels for immune-545 isolation and localization of key modulated SMC populations to facilitate further functional and 546 translational studies.

547

548 Our work expands on recent advancements in flow cytometry and CyTOF that have improved our understanding of atherosclerosis by revealing the diversity of cell types in this disease<sup>8,32,33</sup> 549 550 and also contributes beyond those made to date by single-cell genomic technologies, as exemplified in the work by Fernandez et al.<sup>8</sup> and Depuydt et al.<sup>9</sup>. These studies have enhanced 551 our knowledge of cellular heterogeneity and regulatory networks in atherosclerosis<sup>8,9,26,34-43</sup>. 552 553 Fernandez et al.<sup>8</sup> used CyTOF, scRNA-seq, and selective CITE-seq to investigate immune cell diversity in human carotid atherosclerosis, but their study lacked nonimmune cells and only 554 single-cell profiled 6 patients. Depuydt et al.<sup>9</sup> expanded the scRNA-seg analysis to 18 patients. 555 556 including immune and nonimmune cells, and performed scATAC-seq to identify transcriptional 557 regulators. However, both studies lacked detailed phenotypic characterization of cell types 558 within lesions, which is critical for understanding their roles in the disease.

559

560 Despite extensive evidence in mouse and human atherosclerosis that SMC, SMC-derived cells, and fibroblasts comprise the majority of cells within atherosclerotic lesions<sup>53</sup>, single-cell 561 562 profiling studies in humans have focused primarily on leukocytes. To address this gap, we 563 performed a comprehensive characterization of SMCs and fibroblasts in human lesions. Our 564 analysis identified unique surface proteins, including CD29 and EGFR, that are expressed 565 universally across these cell types, while CD90 was specific to modulated SMCs and fibroblasts, 566 and CD142 was not expressed on the modulated SMC population. These findings enable 567 isolation of these cell types by flow cytometry and determination of the spatial location of each 568 cell type within atherosclerotic tissue, thereby providing critical insight into their functions and 569 potential cell-cell interactions. Sub-clustering analysis revealed previously unknown 570 heterogeneity, including two major contractile SMC and two modulated SMC subpopulations 571 (foamy and fibromyocyte). Mouse models suggest that fibromyocytes contribute to plaque stabilization<sup>35</sup>, while the role of SMC-derived foam cells remains unclear. Our preliminary 572 573 evidence suggests that SMC-derived foam cells are localized to the neointima of advanced 574 coronary lesions, not the fibrous cap, shedding light on their possible functions and lesion 575 domain interactions in atherosclerotic lesion subdomains.

576

577 Our extensive plaque characterization suggests that macrophages are the predominant 578 leukocyte population, contrary to findings from Fernandez et al. and Depuydt et al., who 579 identified T cells as the most abundant immune cell type in lesions. Previous scRNA-seq studies of mouse and human lesions indicated a higher prevalence of myeloid cells than T cells<sup>35,38,39</sup>. 580 581 highlighting the need for standardization of sample processing, analytical methods, and 582 detailed cross-species comparisons. Using protein and gene expression, we identified distinct 583 phenotypic, functional, and activation states of plaque macrophages. Sub-clustering analysis confirmed two proinflammatory macrophage subsets (IL1B<sup>hi</sup> and C1Q<sup>hi</sup>) with enriched 584 inflammatory pathways, consistent with other single-cell studies in different disease contexts<sup>44</sup>. 585 586 The *IL1B*<sup>hi</sup> subset exhibited the most distinct inflammatory gene and protein expression profile, 587 including the genes IL1B, NLRP3, CCR2, and the protein CD192. This suggests that IL1B targeting with canakinumab, which reduced CVD events in the CANTOS trial<sup>45</sup>, may act preferentially on 588 589 these macrophages. Of further translational relevance, our recent work in mice with 590 collaborators suggests that inhibiting IL1B in individuals with clonal hematopoiesis (CH) could 591 effectively reduce CH-driven CVD risk by targeting inflammatory macrophages<sup>46</sup>.

592

593 Our macrophage findings support, in part, a recent transformative study in mice that identified 594 nonfoamy macrophages as having a distinct proinflammatory transcriptome and suggested that 595 lipid accumulation in macrophages may not be a driver of plaque inflammation and 596 vulnerability<sup>36</sup>. Yet our data suggest complex functions for macrophage foam cell sub-types. We 597 discovered two distinct foamy macrophage types in lesions. Foamy 1 had a classic foam cell 598 phenotype with enriched lipid metabolism genes (ABCA1, LPL, FABP5) and high CD36 protein 599 expression. This population predominantly expressed TREM2, which is proposed to protect against atherosclerosis by facilitating cholesterol metabolism through inducing expression of 600 APOE, LPL, and LIPA, while simultaneously reducing inflammation<sup>47</sup>. However, in potential 601 602 conflict with this model, a recent preprint revealed that macrophage-specific deletion of Trem2 in mice reduced atherosclerosis progression and plague burden<sup>48</sup> suggesting that TREM2 may 603 604 be atherogenic at least under certain circumstances. These studies highlight the critical need for 605 additional research in this area e.g., to determine if Trem2 agonism or antagonism and under 606 what circumstances is a viable approach for preventing atherosclerosis. In this context, our 607 Foamy 2 macrophage population expressed TREM2 and certain foam cell genes (APOE) as well 608 as C1Q genes, indicating an intermediate state between Foamy 1 and inflammatory C1Q<sup>hi</sup> 609 populations. In fact, we identified more than one cluster in our initial analysis (Macrophage 1 610 and 5) that had intermediate expression of genes involved in both inflammation and lipid 611 metabolism. Further research is needed to understand the functions of these foamy-612 inflammatory macrophage types and their impact on disease progression and clinical events.

613

We found a macrophage subpopulation expressing proliferative genes, like the stem-like macrophages identified in murine atherosclerosis through fate-mapping<sup>49</sup>. Macrophage proliferation is prominent in advanced stage atherosclerosis in mice<sup>50</sup> and can also occur distinctly during lipid-induced regression and plaque stabilization<sup>51</sup>. Thus, this proliferative population may be responsible for local macrophage proliferation in advanced human atherosclerosis or may act as a transitional cell state giving rise to various phenotypes, including macrophages involved in plaque regression and stabilization. These findings highlight the

621 diversity and complexity of macrophage subtypes within plaques<sup>52</sup>, emphasizing opportunities 622 but significant uncertainties in targeting specific macrophage populations with precision 623 therapeutics.

624

625 Our study supports the concept of marked cell type transitions in human atherosclerosis. We 626 identified a small (~6% of all macrophages) but distinct population of macrophages that 627 expressed SMC-specific genes and displayed a fibrotic pathway phenotype regulated by known SMC transcription factors<sup>26,54</sup>. Interestingly, these macrophages also expressed classic 628 629 macrophage proteins, which has been observed previously in advanced human coronary 630 atherosclerosis<sup>30</sup>, suggesting they are of SMC origin. This finding aligns with previous mouse 631 studies showing SMC plasticity during atherosclerosis progression, including SMC-derived macrophages, fibroblasts, osteogenic cells as well as foam cells<sup>31,34,35,39</sup>. Additionally, we 632 633 identified a substantial population of SMC and likely SMC-derived cells that had a foam cell 634 gene signature, with specific expression of genes involved in lipid metabolism, agreeing with 635 recent studies suggesting that a large portion of foam cells within atherosclerotic plaques may be of SMC origin<sup>30,31</sup>. We also observed two distinct EC populations, with one showing 636 637 upregulated fibrotic pathway genes suggestive of endothelial-to-mesenchymal transition. Our 638 findings provide human evidence that supports recent studies in mice, highlighting the heterogeneity and transitions of ECs during atherosclerosis<sup>34</sup>. Importantly, this EC 639 640 pathophysiological process has been linked to increased disease severity in mouse models of atherosclerosis and in human coronary disease<sup>55,56</sup>. 641

642

643 We found that specific cell-type alterations may associate with symptomatic clinical events. Our 644 clinical analyses, however, may have limitations due to small sample sizes, patient selection 645 biases, and time delays between cerebrovascular events and surgeries. Despite limitations, we 646 observed decreases in efferocytotic macrophages, activated ECs, contractile SMCs, and foamy 647 modulated SMCs, along with an increase in inflammatory SMCs in symptomatic plaques. These 648 alterations indicate a loss of efferocytotic macrophages, erosion of the EC monolaver, and a 649 shift towards an inflammatory SMC/SMC-derived state, in plaque vulnerability<sup>2</sup>. Additionally, 650 macrophages in symptomatic plaques showed increased senescence, also reported to associate 651 with plaque vulnerability<sup>57,58</sup>. SMCs in symptomatic plaques exhibited an increased glycolytic 652 gene signature, extending prior findings of altered metabolism in plaques overall of high-risk 653 patients<sup>59</sup>. As a corollary, alterations in bioenergetic mechanisms in mouse models of 654 atherosclerosis have been found to control SMC differentiation and to be associated with features of plaque instability<sup>21,60</sup>. These clinical associations provide the foundation for pre-655 656 clinical and therapeutic studies targeting specific cell types and molecular programs to improve 657 outcomes in atherosclerotic CVD, particularly in high-risk patients unresponsive to lipid-658 lowering therapy.

659

Although our dataset provides extensive insights into human carotid atherosclerosis, its sample size is still limited and prone to technical biases and artifacts. Findings need to be further corroborated in human coronary arteries and for cardiac events. To gain more confidence in identifying causal alterations associated with clinical CVD events, it is also crucial to increase the number of patient samples and diversity, and to utilize advanced computational and integrative

genomics methods and large-scale human genetics. These integrative studies can help identify
 specific cell types and molecular programs that play a causal role, enabling mechanism-based
 translation for clinical and therapeutic applications.

668

669 In summary, we present the most advanced in-depth multimodal atlas of advanced human 670 carotid atherosclerosis, reveal a vast cell-type heterogeneity of macrophages, SMCs, and 671 fibroblasts, and identify cell type-specific alterations associated with clinical events. We 672 characterized SMC and fibroblasts in unprecedented depth, revealing 3 populations of 673 phenotypically modulated SMCs, including a foamy population that resides in the deep intima 674 of the developing lesion. Further, we have uncovered complex macrophage subpopulations 675 with distinct gene, protein, and transcriptional regulatory features. These data are foundational 676 for future studies mapping CVD susceptible loci to specific cell types, with the goal of identifying 677 new CVD targets specific for certain cell populations fundamental to the progression and 678 regression of disease. Such integrative approaches provide the analytical and conceptional 679 framework for the discovery of novel therapeutics that target specific cell populations in CVD.

680

# 681 Acknowledgements

682

683 The scRNA-seg and CITE-seg (10x Genomics) was performed in the JP Sulzberger Columbia 684 Genome Center, supported in part through the National Institutes of Health/National Cancer 685 Institute Cancer Center Support Grant P30CA013696, and used the Genomics and High 686 Throughput Screening Shared Resource. Flow cytometry experiments described in this article 687 were performed in the Columbia Stem Cell Initiative Flow Cytometry core facility at Columbia 688 University Irving Medical Center. Confocal images were collected in the Confocal and 689 Specialized Microscopy Shared Resource of the Herbert Irving Comprehensive Cancer Center at 690 Columbia University, supported by National Institutes of Health (NIH) grant no. P30 CA013696 691 (National Cancer Institute). 692

- 693 Sources of Funding
- 694

A.C.B. is supported by the National Institute of Health Postdoctoral Training in Arteriosclerosis
fellowship (5T32HL007343). M.L. is supported by National Institutes of Health grant Nos.
R01GM125301, R01HL113147, R01HL150359, and R21HL156234. M.P.R. is supported for this
work by National Institutes of Health grant Nos. R01HL113147, R01HL150359, and
R01HL166916. A.C. is support by American Heart Association Predoctoral Fellowship 909206.
R.C.B. is supported for this work by National Institutes of Health grant Nos. R01HL141745 and
R01DK134026

## 702 References

#### 703

1. Libby, P. The changing landscape of atherosclerosis. *Nature* **592**, 524-533 (2021).

- 7052.Bentzon, J.F., Otsuka, F., Virmani, R. & Falk, E. Mechanisms of plaque formation and706rupture. *Circ Res* **114**, 1852-1866 (2014).
- 7073.Burke, A.P., et al. Coronary risk factors and plaque morphology in men with coronary708disease who died suddenly. N Engl J Med 336, 1276-1282 (1997).
- 7094.Finn, A.V., Nakano, M., Narula, J., Kolodgie, F.D. & Virmani, R. Concept of710vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol **30**, 1282-1292 (2010).
- Aragam, K.G., *et al.* Discovery and systematic characterization of risk variants and genes
  for coronary artery disease in over a million participants. *Nat Genet* 54, 1803-1815
  (2022).
- 6. Getz, G.S. & Reardon, C.A. Animal models of atherosclerosis. *Arterioscler Thromb Vasc Biol* 32, 1104-1115 (2012).
- 716 7. Stoeckius, M., et al. Simultaneous epitope and transcriptome measurement in single
  717 cells. *Nat Methods* 14, 865-868 (2017).
- 718 8. Fernandez, D.M., *et al.* Single-cell immune landscape of human atherosclerotic plaques.
  719 *Nat Med* 25, 1576-1588 (2019).
- 7209.Depuydt, M.A.C., et al. Microanatomy of the Human Atherosclerotic Plaque by Single-721Cell Transcriptomics. Circ Res 127, 1437-1455 (2020).
- 722
   10.
   Hao, Y., et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587

   723
   e3529 (2021).
- Wolf, F.A., Angerer, P. & Theis, F.J. SCANPY: large-scale single-cell gene expression data
  analysis. *Genome Biol* 19, 15 (2018).
- 726
   12.
   Stuart, T., et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-1902

   727
   e1821 (2019).
- 13. Lakkis, J., et al. A joint deep learning model enables simultaneous batch effect
  correction, denoising, and clustering in single-cell transcriptomics. *Genome Res* 31,
  1753-1766 (2021).
- 73114.Cossarizza, A., et al. Guidelines for the use of flow cytometry and cell sorting in732immunological studies (third edition). Eur J Immunol **51**, 2708-3145 (2021).
- 733 15. Dobnikar, L., *et al.* Disease-relevant transcriptional signatures identified in individual
  734 smooth muscle cells from healthy mouse vessels. *Nat Commun* 9, 4567 (2018).
- 16. Lakkis, J., et al. A multi-use deep learning method for CITE-seq and single-cell RNA-seq
  data integration with cell surface protein prediction and imputation. Nat Mach Intell 4,
  940-+ (2022).
- 17. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
  for RNA-seq data with DESeq2. *Genome Biol* 15, 550 (2014).
- 74018.Tirosh, I., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-741cell RNA-seq. Science **352**, 189-196 (2016).
- 742 19. Martinez, F.O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the
  743 human monocyte-to-macrophage differentiation and polarization: new molecules and
  744 patterns of gene expression. *J Immunol* **177**, 7303-7311 (2006).

- Z0. Liu, Y., Beyer, A. & Aebersold, R. On the Dependency of Cellular Protein Levels on mRNA
  Abundance. *Cell* 165, 535-550 (2016).
- 747 21. Newman, A.A.C., *et al.* Multiple cell types contribute to the atherosclerotic lesion fibrous
  748 cap by PDGFRbeta and bioenergetic mechanisms. *Nat Metab* 3, 166-181 (2021).
- 749 22. Ivashkiv, L.B. IFNgamma: signalling, epigenetics and roles in immunity, metabolism,
  750 disease and cancer immunotherapy. *Nat Rev Immunol* 18, 545-558 (2018).
- Z3. Li, Q. & Verma, I.M. NF-kappaB regulation in the immune system. *Nat Rev Immunol* 2, 752
  725-734 (2002).
- 753 24. Staus, D.P., Blaker, A.L., Taylor, J.M. & Mack, C.P. Diaphanous 1 and 2 regulate smooth
  754 muscle cell differentiation by activating the myocardin-related transcription factors.
  755 *Arterioscler Thromb Vasc Biol* 27, 478-486 (2007).
- 75625.Lockman, K., et al.Sphingosine1-phosphatestimulatessmoothmusclecell757differentiation and proliferation by activating separateserum responsefactorco-758factors. J Biol Chem279, 42422-42430 (2004).
- Cheng, P., et al. Smad3 regulates smooth muscle cell fate and mediates adverse
  remodeling and calcification of the atherosclerotic plaque. *Nat Cardiovasc Res* 1, 322333 (2022).
- 762 27. Morrow, D., et al. Notch and vascular smooth muscle cell phenotype. Circ Res 103, 1370-1382 (2008).
- Williams, J.W., Giannarelli, C., Rahman, A., Randolph, G.J. & Kovacic, J.C. Macrophage
  Biology, Classification, and Phenotype in Cardiovascular Disease: JACC Macrophage in
  CVD Series (Part 1). *J Am Coll Cardiol* **72**, 2166-2180 (2018).
- 767 29. Chou, E.L., *et al.* Aortic Cellular Diversity and Quantitative Genome-Wide Association
  768 Study Trait Prioritization Through Single-Nuclear RNA Sequencing of the Aneurysmal
  769 Human Aorta. *Arterioscler Thromb Vasc Biol* 42, 1355-1374 (2022).
- Allahverdian, S., Chehroudi, A.C., McManus, B.M., Abraham, T. & Francis, G.A.
  Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. *Circulation* 129, 1551-1559 (2014).
- Wang, Y., et al. Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE
  (Apolipoprotein E)-Deficient Mouse Atherosclerosis. Arterioscler Thromb Vasc Biol 39,
  876-887 (2019).
- 32. Shankman, L.S., *et al.* KLF4-dependent phenotypic modulation of smooth muscle cells
  has a key role in atherosclerotic plaque pathogenesis. *Nat Med* 21, 628-637 (2015).
- 33. Hamers, A.A.J., *et al.* Human Monocyte Heterogeneity as Revealed by High-Dimensional
  Mass Cytometry. *Arterioscler Thromb Vasc Biol* **39**, 25-36 (2019).
- Alencar, G.F., et al. Stem Cell Pluripotency Genes Klf4 and Oct4 Regulate Complex SMC
  Phenotypic Changes Critical in Late-Stage Atherosclerotic Lesion Pathogenesis. *Circulation* 142, 2045-2059 (2020).
- Wirka, R.C., *et al.* Atheroprotective roles of smooth muscle cell phenotypic modulation
  and the TCF21 disease gene as revealed by single-cell analysis. *Nat Med* 25, 1280-1289
  (2019).
- 786 36. Kim, K., et al. Transcriptome Analysis Reveals Nonfoamy Rather Than Foamy Plaque
  787 Macrophages Are Proinflammatory in Atherosclerotic Murine Models. *Circ Res* 123, 1127-1142 (2018).

- 789 37. Cochain, C., *et al.* Single-Cell RNA-Seq Reveals the Transcriptional Landscape and
  790 Heterogeneity of Aortic Macrophages in Murine Atherosclerosis. *Circ Res* 122, 1661791 1674 (2018).
- 79238.Zernecke, A., et al. Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse793Aortas. Circ Res 127, 402-426 (2020).
- 794 39. Pan, H., *et al.* Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell
  795 Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse
  796 and Human. *Circulation* 142, 2060-2075 (2020).
- 797 40. Conklin, A.C., *et al.* Meta-Analysis of Smooth Muscle Lineage Transcriptomes in
  798 Atherosclerosis and Their Relationships to In Vitro Models. *Immunometabolism* 3(2021).
- 799 41. Ord, T., *et al.* Single-Cell Epigenomics and Functional Fine-Mapping of Atherosclerosis
  800 GWAS Loci. *Circ Res* **129**, 240-258 (2021).
- 801 42. Slenders, L., *et al.* Intersecting single-cell transcriptomics and genome-wide association
  802 studies identifies crucial cell populations and candidate genes for atherosclerosis. *Eur*803 *Heart J Open* 2, oeab043 (2022).
- 80443.Ma, W.F., et al. Enhanced single-cell RNA-seq workflow reveals coronary artery disease805cellular cross-talk and candidate drug targets. Atherosclerosis 340, 12-22 (2022).
- 80644.Mulder, K., et al. Cross-tissue single-cell landscape of human monocytes and807macrophages in health and disease. Immunity 54, 1883-1900 e1885 (2021).
- 80845.Ridker, P.M., et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic809Disease. N Engl J Med 377, 1119-1131 (2017).
- 81046.Fidler, T.P., et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal811haematopoiesis. Nature 592, 296-301 (2021).
- 812 47. Endo-Umeda, K., et al. Myeloid LXR (Liver X Receptor) Deficiency Induces Inflammatory
  813 Gene Expression in Foamy Macrophages and Accelerates Atherosclerosis. Arterioscler
  814 Thromb Vasc Biol 42, 719-731 (2022).
- 81548.Patterson, M.T., et al. Trem2 Promotes Foamy Macrophage Lipid Uptake and Survival in816Atherosclerosis. bioRxiv, 2022.2011.2028.518255 (2022).
- 49. Lin, J.D., *et al.* Single-cell analysis of fate-mapped macrophages reveals heterogeneity,
  including stem-like properties, during atherosclerosis progression and regression. *JCI Insight* 4(2019).
- 82050.Robbins, C.S., et al. Local proliferation dominates lesional macrophage accumulation in<br/>atherosclerosis. Nat Med 19, 1166-1172 (2013).
- 82251.Gerlach, B.D., et al. Efferocytosis induces macrophage proliferation to help resolve823tissue injury. Cell Metab 33, 2445-2463 e2448 (2021).
- 52. Vallejo, J., Cochain, C., Zernecke, A. & Ley, K. Heterogeneity of immune cells in human atherosclerosis revealed by scRNA-Seq. *Cardiovasc Res* **117**, 2537-2543 (2021).
- 826 53. Wissler, R.W. The arterial medial cell, smooth muscle, or multifunctional mesenchyme?
  827 *Circulation* 36, 1-4 (1967).
- 82854.Cheng, P., et al. ZEB2 Shapes the Epigenetic Landscape of Atherosclerosis. Circulation829145, 469-485 (2022).
- 83055.Chen, P.Y., et al. Endothelial-to-mesenchymal transition drives atherosclerosis831progression. J Clin Invest 125, 4514-4528 (2015).

- 832 56. Evrard, S.M., *et al.* Endothelial to mesenchymal transition is common in atherosclerotic
  833 lesions and is associated with plaque instability. *Nat Commun* 7, 11853 (2016).
- 834 57. Childs, B.G., *et al.* Senescent intimal foam cells are deleterious at all stages of atherosclerosis. *Science* **354**, 472-477 (2016).
- Tabas, I. & Lichtman, A.H. Monocyte-Macrophages and T Cells in Atherosclerosis. *Immunity* 47, 621-634 (2017).
- 83859.Tomas, L., et al. Altered metabolism distinguishes high-risk from stable carotid839atherosclerotic plaques. Eur Heart J **39**, 2301-2310 (2018).
- 84060.Mayr, M., et al. Proteomic and metabolomic analyses of atherosclerotic vessels from841apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and842energy metabolism. Arterioscler Thromb Vasc Biol **25**, 2135-2142 (2005).
- 843



**Figure 1. Multiomic analysis of human carotid atherosclerosis identifies 25 distinct cell populations.** (A) Experimental design. (B) UMAP visualization of clustering revealed 25 cell populations. (C) Canonical Proteins to identify macrophages, T cells, NK cells, B Cells, Plasma Cells, Mast Cells, Neutrophils, dendritic cells, and endothelial cells. (D) Canonical Genes to identify SMCs and Fibroblasts. (E) Distribution of each major subclass across all samples.



**Figure 2. Multimodal biomarkers of cells within carotid atherosclerotic plaques.** (A) Heatmap of all cell types identified in carotid atherosclerosis. Markers include top 10 mRNA (Left) and top 10 protein (Right) features identified by differential expression. (B) Feature plots displaying unique protein markers for SMCs (Top) and fibroblasts (bottom). (C) Flow cytometry validation of predicted protein markers for SMC 1-3, modulated SMC, and fibroblasts. (D) Feature plots displaying proteins to differentiate endothelial cell 1 and endothelial cell 2. (E) Pathway analysis comparing endothelial cell 1 and endothelial 2 using genes from differential expression analysis.



**Figure 3. Cerebrovascular events are associated with alterations in the distribution of certain cell populations.** (A) UMAP colored by clinical status. (B) Vertical bar graph showing proportion of all clusters by clinical status. (C) Box Plots showing distribution of select cell populations including macrophage 1, endothelial cell 1, SMC 2, SMC 3, and modulated SMC. (D) Gene scoring analysis comparing senescence in macrophage clusters in asymptomatic and symptomatic plaques. (E) Gene scoring analysis comparing glycolysis in SMC and fibroblast clusters in asymptomatic and symptomatic plaques.



Inflammasome -0.195 -0.1211 -0.1341 -0.1303 -0.2226 -0.0265 0.250 1.25 1.00 0.75 0.50 0.25 0.00 -0.25 -0.50 Proliferative FORMYZ -0.75 APOPTOTIC 11.181 FORMY ACTAZ C10<sup>21</sup>





**Figure 4. Sub-clustering analysis of myeloid cells reveals further macrophage phenotypic and functional heterogeneity.** (A) Sub-clustering analysis of myeloid cells. Macrophage 1-5, pDC, and cDC clusters were selected from the initial clustering analysis, revealing 10 clusters. (B) Heatmap showing top upregulated pathways for each macrophage subpopulation based on top DE genes. (C) Heatmap showing top predicted transcriptional regulators for each macrophage subpopulation. (D) UMAP overlaying expression of common M1 and M2 signatures (left), and violin plots quantifying median expression for each macrophage subpopulation. (E) Gene scoring analysis for inflammasome activation, DNA damage, and efferocytosis across macrophage subpopulations.



**Figure 5. Sub-clustering of SMC and Fibroblasts reveals distinct subpopulations.** (A) Subclustering analysis of SMC and fibroblasts. SMC 1-3, modulated SMC, and fibroblast clusters were selected from the initial analysis, revealing 10 clusters. (B) Dotplot showing expression of classic SMC genes with corresponding phenotypes. (C) Radar plot showing pathways for SMCs obtained from DE genes. (D) Radar plot showing pathways for fibroblasts obtained from DE genes. (E) Immunohistochemistry staining targeting foamy SMC markers in coronary artery section. DAPI (blue), Smoothelin (green), LipidTOX (red), and CD90 (magenta). White arrows indicate Smoothelin<sup>+</sup>LipidTOX<sup>+</sup>CD90<sup>+</sup> cells in neointima region of lesion. n=1. (F) Box plots showing distribution of select cell populations including foamy SMC, minor SMC 2, and fibromyocyte comparing asymptomatic and symptomatic plaques.